Andulf has advised lead investor Mr. Pablo Legorreta in connection with the recently completed equity investment of in the aggregate up to $67 million in ITB-Med AB (publ). The capital injection will be used to develop the company’s core asset Siplizumab in its lead indication of induction of tolerance in organ transplantation. Pablo Legorreta is the Founder & CEO of Royalty Pharma. With over $18 billion in assets, Royalty Pharma is the largest life sciences investment firm as well as the industry leader in the acquisition of royalties in leading biopharmaceutical products. Andulf's team comprised Martin Pilotti and Mattias Persson.